|
1
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Etti J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole versus letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.
Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel
Members: Tailoring therapies - improving the management of early
breast cancer: St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2015. Ann Oncol.
26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swain SM, Baselga J, Kim SB, Ro J,
Semiglazov VM, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et
al: CLEOPATRA Study Group: Pertuzumab, trastuzumab, and docetaxel
in HER2-positive metastatic breast cancer. N Engl J Med.
372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Turner NC, Ro J, André F, Loi S, Verma S,
Iwata HN, Loibl S, Bartlett Huang C, Zhang K, et al: PALOMA3 Study
Group: Palbociclib in hormone-receptor-positive advanced breast
cancer. N Engl J Med. 373:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hindié E and Groheux D: Regional nodal
irradiation in early-stage breast cancer. N Engl J Med.
373:1877–1878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Narimatsu R and Patterson BK:
High-throughput cervical cancer screening using intracellular human
papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am
J Clin Pathol. 123:716–723. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu TP, Liu XX, Xia R, Yin L, Kong R, Chen
WM, Huang MD and Shu YQ: SP1-induced upregulation of the long
noncoding RNA TINCR regulates cell proliferation and apoptosis by
affecting KLF2 mRNA stability in gastric cancer. Oncogene.
34:5648–5661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim KT, Lee HW, Lee HO, Kim SC, Seo YJ,
Chung W, Eum HH, Nam DH, Kim J, Joo KM, et al: Single-cell mRNA
sequencing identifies subclonal heterogeneity in anti-cancer drug
responses of lung adenocarcinoma cells. Genome Biol. 16:1272015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y,
Wang L, Wang S, He Q, Huang J, et al: Down-regulation of c-Met and
Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell
proliferation, migration and colony formation. Oncotarget.
6:25533–25574. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sparano JA, Gray RJ, Makower DF, Pritchard
KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA
Jr, et al: Prospective validation of a 21-gene expression assay in
breast cancer. N Engl J Med. 373:2005–2014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Poortmans PM, Collette S, Kirkove C, Van
Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A,
Maingon P, Valli M, et al: EORTC Radiation Oncology and Breast
Cancer Groups: Internal mammary and medial supraclavicular
irradiation in breast cancer. N Engl J Med. 373:317–327. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tutt A, Ellis P, Kilburn L, Gilett C,
Pinder S, Abraham J, Barrett S, Barrett-Lee P, Chan S and Cheang M:
The TNT trial: A randomized phase III trial of carboplatin (C)
compared with docetaxel (D) for patients with metastatic or
recurrent locally advanced triple negative or BRCA1/2 breast cancer
(CRUK/07/012). Cancer Res. 75 9 Suppl:Abst S3-01. 2015. View Article : Google Scholar
|
|
15
|
Huang X, Yuan T, Liang M, Du M, Xia S,
Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal
miR-1290 and miR-375 as prognostic markers in castration-resistant
prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zargar H, Espiritu PN, Fairey AS, Mertens
LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi
NM, et al: Multicenter assessment of neoadjuvant chemotherapy for
muscle-invasive bladder cancer. Eur Urol. 67:241–249. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta Y, Möller S, Witte M, Belheouane M,
Sezin T, Hirose M, Vorobyev A, Niesar F, Bischof J, Ludwig RJ, et
al: Dissecting genetics of cutaneous miRNA in a mouse model of an
autoimmune blistering disease. BMC Genomics. 17:1122016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ge X, Lyu P, Cao Z, Li J, Guo G, Xia W and
Gu Y: Overexpression of miR-206 suppresses glycolysis,
proliferation and migration in breast cancer cells via PFKFB3
targeting. Biochem Biophys Res Commun. 463:1115–1121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eades G, Wolfson B, Zhang Y, Li Q, Yao Y
and Zhou Q: lincRNA-RoR and miR-145 regulate invasion in
triple-negative breast cancer via targeting ARF6. Mol Cancer Res.
13:330–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim TH, Song JY, Park H, Jeong JY, Kwon
AY, Heo JH, Kang H, Kim G and An HJ: miR-145, targeting
high-mobility group A2, is a powerful predictor of patient outcome
in ovarian carcinoma. Cancer Lett. 356:(2 Pt B). 1–945. 2015.
View Article : Google Scholar
|
|
21
|
Oksuz Z, Serin MS, Kaplan E, Dogen A,
Tezcan S, Aslan G, Emekdas G, Sezgin O, Altintas E and Tiftik EN:
Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p
could be used as novel non-invasive biomarkers for HCV-positive
cirrhosis and hepatocellular carcinoma. Mol Biol Rep. 42:713–720.
2015. View Article : Google Scholar : PubMed/NCBI
|
